Genetic Basis of Hemangiomas

Hemangioma, Vascular Anomalies Clinical Trial

Official title:

Genetic Basis of Hemangiomas

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00466375
• Other study ID #: Genetics of Hemangioma
• Status: Terminated
• Phase: N/A
• First received: April 25, 2007
• Last updated: August 28, 2017
• Start date: April 2007
• Est. completion date: May 2016

Study information

• Verified date: August 2017
• Source: Medical College of Wisconsin
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine if there are genes that are common in children with infantile hemangioma. This information will allow physicians to improve care for patients who have been diagnosed with this disease and to provide their parents with more complete information regarding the cause of this disease. This research is being done because many unanswered questions remain regarding children with infantile hemangioma. There are very few medications to treat infants with hemangiomas.

Description:

WHAT IS INVOLVED IN THE RESEARCH STUDY?

• Buccal smear (cheek cells) or small blood sample (4 mL or 1 teaspoon) from child being seen in the Dermatology clinic having infantile hemangioma or vascular anomaly

• Buccal smear (cheek cells) or small blood sample (4 mL or 1 teaspoon) from parents of child

If you and your child agree to be in this study, the following will happen:

1. Informed consent and permission to use or disclose your/your child's health information for research purposes will be obtained by Dr. Drolet, the principal investigator, or her research team. You will receive a copy of this consent form.

2. A buccal swab or blood sample will be obtained from you and your child; buccal sampling involves rubbing the inside of your cheek and removing cells to perform a genetic test called "Genomewide Association (GWA).

We expect you and your child to be involved in this study until you and your child have the genetic testing performed.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 300
• Est. completion date: May 2016
• Est. primary completion date: November 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Study Population Inclusion Criteria:

• No limit to age

• Diagnosis of infantile hemangioma and/or vascular anomaly

• Unaffected twin sibling

• Each patient's authorized legal guardian must understand the nature of the study and must provide written informed consent. Each patient must also give assent to study participation.

Study Population Exclusion Criteria:

• Diagnosis other than infantile hemangioma or vascular anomaly

• If the lesion has resolved and cannot be confirmed as a hemangioma by clinical exam

• If the biologic parents are unwilling or unable to submit DNA samples the child will be excluded from the DNA study. Therefore, if DNA samples cannot be or are not obtained from both biologic parents, the child and family will be excluded from the study.

Related Conditions & MeSH terms

• Congenital Abnormalities
• Hemangioma
• Hemangioma, Vascular Anomalies
• Vascular Malformations

Intervention

Genetic:
• Cheek cell samples or blood sample (4mL)
DNA will be extracted from cheek cell or blood samples from parents and child having hemangioma.
• Cheek cell sample or blood sample (4mL)
DNA will be extracted from cheek cell or blood samples of parents and child with a vascular anomaly.

Locations

Country	Name	City	State
United States	Children's Hospital of Wisconsin	Milwaukee	Wisconsin

Sponsors (2)

Lead Sponsor	Collaborator
Medical College of Wisconsin	Children's Hospital and Health System Foundation, Wisconsin

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SNP		3 years